Phaseline

Companies › SPH Qingdao Growful Pharmacetical

SPH Qingdao Growful Pharmacetical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Cardiovascular; next expected readout Aug 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Yangxinshi tablet–Phase 4Coronary Heart Disease; Chronic Coronary SyndromeAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06171061Yangxinshi tabletPhase 4Chronic Coronary SyndromeCardiovascularDec 2026
NCT07110415Yangxinshi tabletPhase 4Coronary Heart DiseaseCardiovascularAug 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CeleCor Therapeutics MedTrace Pharma Hanlim Pharm. Trust Bio-sonics Liquidia Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.